What the lab can and cannot do: clinical interpretation of drug testing results

References

• Dole VP, Nyswander M. A medical treatment for diacetylmorphine (Heroin) Addiction. A clinical trial with methadone hydrochloride. JAMA. 1965;193:646–650.
   PubMed Web of Science ®Google Scholar
• Langman LJ, Kapur BM. Toxicology: then and now. Clin Biochem. 2006;39(5):498–510.
   PubMed Web of Science ®Google Scholar
• Christo PJ, Manchikanti L, Ruan X, et al. Urine drug testing in chronic pain. Pain Physician. 2011;14(2):123–143.
   PubMed Web of Science ®Google Scholar
• Nuckols TK, Anderson L, Popescu I, et al. Opioid prescribing: a systematic review and critical appraisal of guidelines for chronic pain. Ann Intern Med. 2014;160(1):38–47.
   PubMed Web of Science ®Google Scholar
• Turner JA, Saunders K, Shortreed SM, et al. Chronic opioid therapy urine drug testing in primary care: prevalence and predictors of aberrant results. J Gen Intern Med. 2014;29(12):1663–1671.
   PubMed Web of Science ®Google Scholar
• Dupouy J, Memier V, Catala H, et al. Does urine drug abuse screening help for managing patients? A systematic review. Drug Alcohol Depend. 2014;136:11–20.
   PubMed Web of Science ®Google Scholar
• Shah RR, Smith RL. Addressing phenoconversion: the Achilles' heel of personalized medicine. Br J Clin Pharmacol. 2015;79(2):222–240.
   PubMed Web of Science ®Google Scholar
• Israili ZH, Dayton PG. Human alpha-1-glycoprotein and its interactions with drugs. Drug Metab Rev. 2001;33(2):161–235.
   PubMed Web of Science ®Google Scholar
• Musteata FM. Measuring and using free drug concentrations: has there been 'real' progress? Bioanalysis. 2017;9(10):767–769.
   PubMed Web of Science ®Google Scholar
• Toennes SW, Maurer HH. Efficient cleavage of conjugates of drugs or poisons by immobilized beta-glucuronidase and arylsulfatase in columns. Clin Chem. 1999;45(12):2173–2182.
   PubMed Web of Science ®Google Scholar
• Kang MG, Lin HR. Systematic evaluation and validation of benzodiazepines confirmation assay using LC-MS-MS. J Anal Toxicol. 2019;43(2):96–103.
   PubMed Web of Science ®Google Scholar
• Sitasuwan P, Melendez C, Marinova M, et al. Comparison of Purified beta-glucuronidases in patient urine samples indicates a lack of correlation between enzyme activity and drugs of abuse metabolite hydrolysis efficiencies leading to potential false negatives. J Anal Toxicol. 2019;43(3):221–227.
   PubMed Web of Science ®Google Scholar
• Muller LD, Opdal MS. Developing a rapid semi-automated sample preparation with alkaline hydrolysis in a 96-well plate for quantification of 11-nor-DELTA9-tetrahydrocannabinol-9-carboxylic acid in urine samples by UHPLC-MS/MS. J Pharm Biomed Anal. 2018;161:296–304.
   PubMed Web of Science ®Google Scholar
• Goggin MM, Tann C-M, Miller A, et al. Catching fakes: new markers of urine sample validity and invalidity. J Anal Toxicol. 2017;41(2):121–126.
   PubMed Web of Science ®Google Scholar
• Jaffee W, Trucco E, Levy S, et al. Is this urine really negative? a systematic review of tampering methods in urine drug screening and testing. J Subst Abuse Treat. 2007;33(1):33–42.
   PubMed Web of Science ®Google Scholar
• Kapur B, Hershkop S, Koren G, et al. Urine fingerprinting: detection of sample tampering in an opiate dependency program. Ther Drug Monit. 1999;21(2):243–250.
   PubMed Web of Science ®Google Scholar
• Fu S. Adulterants in urine drug testing. Adv Clin Chem. 2016;76:123–163.
   PubMed Web of Science ®Google Scholar
• Cook JD, Strauss KA, Caplan YH, et al. Urine pH: the effects of time and temperature after collection. J Anal Toxicol. 2007;31(8):486–496.
   PubMed Web of Science ®Google Scholar
• Feldhammer M, Saitman A, Nguyen L, et al. Dilution of Urine Followed by Adulteration in an Attempt to Deceive the Laboratory. J Anal Toxicol. 2019;43(1):e7–e9.
   PubMed Web of Science ®Google Scholar
• Kim VJ, Okano CK, Osborne CR, et al. Can synthetic urine replace authentic urine to "beat" workplace drug testing? Drug Test Anal. 2019;11(2):331–335.
   PubMed Web of Science ®Google Scholar
• Koren G. Measurement of drugs in neonatal hair; a window to fetal exposure. Forensic Sci Int. 1995;70(1-3):77–82.
   PubMed Web of Science ®Google Scholar
• Kintz P. Issues about axial diffusion during segmental hair analysis. Ther Drug Monit. 2013;35(3):408–410.
   PubMed Web of Science ®Google Scholar
• Saitoh M, Uzuka M, Sakamoto M. Rate of hair growth. Adv Biol Skin Hair Growth. 1967;9:183–194.
   Google Scholar
• Saitoh M, Uzuka M, Sakamoto M. Human hair cycle. J Invest Dermatol. 1970;54(1):65–81.
   PubMed Web of Science ®Google Scholar
• Bailey DN. Drug screening in an unconventional matrix: hair analysis. JAMA. 1989;262(23):3331.
   PubMed Web of Science ®Google Scholar
• Wille SM, Baumgartner MR, Fazio VD, et al. Trends in drug testing in oral fluid and hair as alternative matrices. Bioanalysis. 2014;6(17):2193–2209.
   PubMed Web of Science ®Google Scholar
• Scholz C, Quednow BB, Herdener M, et al. Cocaine hydroxy metabolites in hair: indicators for cocaine use versus external contamination. J Anal Toxicol. 2019;43(7):543–552.
   PubMed Web of Science ®Google Scholar
• Tsanaclis L, Andraus M, Wicks J. Hair analysis when external contamination is in question: a review of practical approach for the interpretation of results. Forensic Sci Int. 2018;285:105–110.
   PubMed Web of Science ®Google Scholar
• Kidwell DA, Smith FP, Shepherd AR. Ethnic hair care products may increase false positives in hair drug testing. Forensic Sci Int. 2015;257:160–164.
   PubMed Web of Science ®Google Scholar
• Hartwig S, Auwarter V, Pragst F. Effect of hair care and hair cosmetics on the concentrations of fatty acid ethyl esters in hair as markers of chronically elevated alcohol consumption. Forensic Sci Int. 2003;131(2-3):90–97.
   PubMed Web of Science ®Google Scholar
• Cuypers E, Flanagan RJ. The interpretation of hair analysis for drugs and drug metabolites. Clin Toxicol. 2018;56(2):90–100.
   PubMed Web of Science ®Google Scholar
• Montgomery DP, Plate CA, Jones M, et al. Using umbilical cord tissue to detect fetal exposure to illicit drugs: a multicentered study in Utah and New Jersey. J Perinatol. 2008;28(11):750–753.
   PubMed Web of Science ®Google Scholar
• Ostrea EM, Jr., Bielawski DM, Posecion NC. Jr. Meconium analysis to detect fetal exposure to neurotoxicants. Arch Dis Child. 2006;91(8):628–629.
   PubMed Web of Science ®Google Scholar
• Colby JM, Cotten SW. Facing challenges in neonatal drug testing. Clinical Laboratory News. 2018. Available from: https://www.aacc.org/publications/cln/articles/2018/march/facing-challenges-in-neonatal-drug-testing
   Google Scholar
• Colby JM, Adams BC, Morad A, et al. Umbilical cord tissue and meconium may not be equivalent for confirming in utero substance exposure. J Pediatr. 2019;205:277–280.
   PubMed Web of Science ®Google Scholar
• Zelner I, Hutson JR, Kapur BM, et al. False-positive meconium test results for fatty acid ethyl esters secondary to delayed sample collection. Alcohol Clin Exp Res. 2012;36(9):1497–1506.
   PubMed Web of Science ®Google Scholar
• Ostrea EM. Jr. Testing for exposure to illicit drugs and other agents in the neonate: a review of laboratory methods and the role of meconium analysis. Curr Probl Pediatr. 1999;29(2):37–56.
   PubMedGoogle Scholar
• Palmer KL, Krasowski MD. Alternate matrices: meconium, cord tissue, hair, and oral fluid. In: Langman LJ, Snozek CLH, editors. LC-MS in drug analysis: methods in molecular biology vol. 1872. New York, NY: Humana Press; 2019. p. 191–197.
   Google Scholar
• Ilea A, Andrei V, Feurdean CN, et al. Saliva, a magic biofluid available for multilevel assessment and a mirror of general health-a systematic review. Biosensors. 2019;9(1):27.
   PubMedGoogle Scholar
• Kaczor-Urbanowicz KE, Martin Carreras-Presas C, Aro K, et al. Saliva diagnostics - current views and directions. Exp Biol Med (Maywood)). 2017;242(5):459–472.
   PubMed Web of Science ®Google Scholar
• Cone EJ, Clarke J, Tsanaclis L. Prevalence and disposition of drugs of abuse and opioid treatment drugs in oral fluid. J Anal Toxicol. 2007;31(8):424–433.
   PubMed Web of Science ®Google Scholar
• Pichini S, Altieri I, Zuccaro P, et al. Drug monitoring in nonconventional biological fluids and matrices. Clin Pharmacokinet. 1996;30(3):211–228.
   PubMed Web of Science ®Google Scholar
• Kidwell DA, Holland JC, Athanaselis S. Testing for drugs of abuse in saliva and sweat. J Chromatogr. 1998;713(1):111–135.
   Web of Science ®Google Scholar
• Abebe W. Khat and synthetic cathinones: emerging drugs of abuse with dental implications. Oral Surg Oral Med Oral Pathol Oral Radiol. 2018;125(2):140–146.
   PubMed Web of Science ®Google Scholar
• Aps JK, Martens LC. Review: the physiology of saliva and transfer of drugs into saliva. Forensic Sci Int. 2005;150(2-3):119–131.
   PubMed Web of Science ®Google Scholar
• Desrosiers NA, Huestis MA. Oral fluid drug testing: analytical approaches, issues and interpretation of results. J Anal Toxicol. 2019;43(6):415–443.
   PubMed Web of Science ®Google Scholar
• Drummer OH, Gerostamoulos J, Batziris H, et al. The incidence of drugs in drivers killed in Australian road traffic crashes. Forensic Sci Int. 2003;134(2-3):154–162.
   PubMed Web of Science ®Google Scholar
• Bakke E, Hoiseth G, Arnestad M, et al. Detection of drugs in simultaneously collected samples of oral fluid and blood. J Anal Toxicol. 2019;43(3):228–232.
   PubMed Web of Science ®Google Scholar
• Mucklow JC, Bending MR, Kahn GC, et al. Drug concentration in saliva. Clin Pharmacol Ther. 1978;24(5):563–570.
   PubMed Web of Science ®Google Scholar
• Bang IC. Ein verfahren zur mikrobestimmung von blutbestandteilen. Biochem Z. 1913;49:19–39. [German]
   Google Scholar
• Guthrie R, Susi A. A simple phenylalanine method for detecting phenylketonuria in large populations of newborn infants. Pediatrics. 1963;32:338–343.
   PubMed Web of Science ®Google Scholar
• Schutz H, Gotta JC, Erdmann F, et al. Simultaneous screening and detection of drugs in small blood samples and bloodstains. Forensic Sci Int. 2002;126(3):191–196.
   PubMed Web of Science ®Google Scholar
• Kumar P, Agrawal P, Chatterjee K. Challenges and opportunities in blood flow through porous substrate:A design and interface perspective of dried blood spot. J Pharm Biomed Anal. 2019;175:112772.
   PubMed Web of Science ®Google Scholar
• Kloosterboer SM, de Winter BCM, Bahmany S, et al. Dried blood spot analysis for therapeutic drug monitoring of antipsychotics: drawbacks of its clinical application. Ther Drug Monit. 2018;40(3):344–350.
   PubMed Web of Science ®Google Scholar
• Ambach L, Menzies E, Parkin MC, et al. Quantification of cocaine and cocaine metabolites in dried blood spots from a controlled administration study using liquid chromatography-tandem mass spectrometry. Drug Test Anal. 2019;11(5):709–720.
   PubMed Web of Science ®Google Scholar
• Duthaler U, Berger B, Erb S, et al. Using dried blood spots to facilitate therapeutic drug monitoring of antiretroviral drugs in resource-poor regions. J Antimicrob Chemother. 2018;73(10):2729–2737.
   PubMed Web of Science ®Google Scholar
• Freeman JD, Rosman LM, Ratcliff JD, et al. State of the science in dried blood spots. Clin Chem. 2018;64(4):656–679.
   PubMed Web of Science ®Google Scholar
• Zakaria R, Allen KJ, et al. Advantages and challenges of dried blood spot analysis by mass spectrometry across the total testing process. J Inter Feder Clin Chem Lab Med. 2016;27(4):288–317.
   Google Scholar
• Velghe S, Delahaye L, Stove CP. Is the hematocrit still an issue in quantitative dried blood spot analysis? J Pharm Biomed Anal. 2019;163:188–196.
   PubMed Web of Science ®Google Scholar
• Denniff P, Spooner N. Volumetric absorptive microsampling: a dried sample collection technique for quantitative bioanalysis. Anal Chem. 2014;86(16):8489–8495.
   PubMed Web of Science ®Google Scholar
• Gaugler S, Al-Mazroua MK, Issa SY, et al. Fully automated forensic routine dried blood spot screening for workplace testing. J Anal Toxicol. 2019;43(3):212–220.
   PubMed Web of Science ®Google Scholar
• Caramelo D, Rosado T, Oliveira V, et al. Determination of antipsychotic drugs in oral fluid using dried saliva spots by gas chromatography-tandem mass spectrometry. Anal Bioanal Chem. 2019;411(23):6141–6153.
   PubMed Web of Science ®Google Scholar
• Ribeiro A, Prata M, Vaz C, et al. Determination of methadone and EDDP in oral fluid using the dried saliva spots sampling approach and gas chromatography-tandem mass spectrometry. Anal Bioanal Chem. 2019;411(10):2177–2187.
   PubMed Web of Science ®Google Scholar
• Rubenstein KE, Schneider RS, Ullman EF. "Homogeneous" enzyme immunoassay. A new immunochemical technique. Biochem Biophys Res Commun. 1972;47(4):846–851.
   PubMed Web of Science ®Google Scholar
• Schneider RS, Lindquist P, Tong-In WE, et al. Homogeneous enzyme immunoassay for opiates in urine. Clin Chem. 1973;19(8):821–825.
   PubMed Web of Science ®Google Scholar
• Cotten SW, Duncan DL, Burch EA, et al. Unexpected interference of baby wash products with a cannabinoid (THC) immunoassay. Clin Biochem. 2012;45(9):605–609.
   PubMed Web of Science ®Google Scholar
• Kapur BM. False positive drugs of abuse immunoassays. Clin Biochem. 2012;45(9):603–604.
   PubMed Web of Science ®Google Scholar
• Bertholf RL, Sharma R, Reisfield GM. Predictive value of positive drug screening results in an urban outpatient population. J Anal Toxicol. 2016;40(9):726–731.
   PubMed Web of Science ®Google Scholar
• Langman LJ, Snozek CLH, editors. LC-MS in drug analysis methods and protocols. New York, Heidelberg, Dordrecht, London: Humana Press, Springer; 2012. p. 1–222.
   Google Scholar
• Nilsson MI, Widerlov E, Meresaar U, et al. Effect of urinary pH on the disposition of methadone in man. Eur J Clin Pharmacol. 1982;22(4):337–342.
   PubMed Web of Science ®Google Scholar
• Arthur CL, Pawliszyn J. Solid phase microextraction with thermal desorption using fused silica optical fibers. Anal Chem. 1990;62(19):2145–2148.
   Web of Science ®Google Scholar
• Pragst F. Application of solid-phase microextraction in analytical toxicology. Anal Bioanal Chem. 2007;388(7):1393–1414.
   PubMed Web of Science ®Google Scholar
• Risticevic S, Lord H, Górecki T, et al. Protocol for solid-phase microextraction method development. Nat Protoc. 2010;5(1):122–139.
   PubMed Web of Science ®Google Scholar
• Azzi-Achkouty S, Estephan N, Ouaini N, et al. Headspace solid-phase microextraction for wine volatile analysis. Crit Rev Food Sci Nutr. 2017;57(10):2009–2020.
   PubMed Web of Science ®Google Scholar
• Hamidi S, Ipour-Ghorbani N, Hamidi A. Solid phase microextraction techniques in determination of biomarkers. Crit Rev Anal Chem. 2018;48(4):239–251.
   PubMed Web of Science ®Google Scholar
• Seidi S, Rezazadeh M, Alizadeh R. Miniaturized sample preparation methods for saliva analysis. Bioanalysis. 2019;11(2):119–148.
   PubMed Web of Science ®Google Scholar
• Ghosh C, Singh V, Grandy J, et al. Recent advances in breath analysis to track human health by new enrichment technologies. J Sep Sci. 2020;43(1):226–240.
   PubMed Web of Science ®Google Scholar
• United Nations Office on Drugs and Crime. UNODC Early Warning Advisory on New Psychoactive Substances. 2020 [cited 2020 Mar 22]. Available from: https://www.unodc.org/LSS/Page/NPS
   Google Scholar
• Graziano S, Anzillotti L, Mannocchi G, et al. Screening methods for rapid determination of new psychoactive substances (NPS) in conventional and non-conventional biological matrices. J Pharm Biomed Anal. 2019;163:170–179.
   PubMed Web of Science ®Google Scholar
• Kraemer M, Boehmer A, Madea B, et al. Death cases involving certain new psychoactive substances: A review of the literature. Forensic Sci Int. 2019;298:186–267.
   PubMed Web of Science ®Google Scholar
• Alexandre J, Carmo H, Carvalho F, et al. Synthetic cannabinoids and their impact on neurodevelopmental processes. Addict Biol. 2020;25(2):e12824.
   PubMed Web of Science ®Google Scholar
• Rinaldi R, Bersani G, Marinelli E, et al. The rise of new psychoactive substances and psychiatric implications: A wide-ranging, multifaceted challenge that needs far-reaching common legislative strategies. Hum Psychopharmacol. 2020;35:e2727.
   PubMed Web of Science ®Google Scholar
• Peacock A, Bruno R, Gisev N, et al. New psychoactive substances: challenges for drug surveillance, control, and public health responses. Lancet. 2019;394(10209):1668–1684.
   PubMed Web of Science ®Google Scholar
• Gerostamoulos D, Elliott S, Walls HC, et al. To measure or not to measure? that is the NPS question. J Anal Toxicol. 2016;40(4):318–320.
   PubMed Web of Science ®Google Scholar
• Jorgenson JW, Lukacs KD. Free-zone electrophoresis in glass capillaries. Clin Chem. 1981;27(9):1551–1553.
   PubMed Web of Science ®Google Scholar
• Barbula GK, Safi S, Chingin K, et al. Interfacing capillary-based separations to mass spectrometry using desorption electrospray ionization. Anal Chem. 2011;83(6):1955–1959.
   PubMed Web of Science ®Google Scholar
• Deterding LJ, Moseley MA, Tomer KB, et al. Nanoscale separations combined with tandem mass spectrometry. J Chromatogr. 1991;554(1-2):73–82.
   PubMed Web of Science ®Google Scholar
• Moini M, Rollman CM. Compatibility of highly sulfated cyclodextrin with electrospray ionization at low nanoliter/minute flow rates and its application to capillary electrophoresis/electrospray ionization mass spectrometric analysis of cathinone derivatives and their optical isomers. Rapid Commun Mass Spectrom. 2015;29(3):304–310.
   PubMed Web of Science ®Google Scholar
• DiBattista A, Rampersaud D, Lee H, et al. High throughput screening method for systematic surveillance of drugs of abuse by multisegment injection-capillary electrophoresis-mass spectrometry. Anal Chem. 2017;89(21):11853–11861.
   PubMed Web of Science ®Google Scholar
• Kapur BM, Allgeier H, Reichstein T. [The glycosides of the roots from Kanahia laniflora (Forssk.) R. Br. 1. Isolation]. [German]. Helv Chim Acta. 1967;50(7):2147–2171.
   PubMedGoogle Scholar
• Kondrat RW, McClusky GA, Cooks RG. Multiple reaction monitoring in mass spectrometry/mass spectrometry for direct analysis of complex mixtures. Anal Chem. 1978;50(14):2017–2021.
   Web of Science ®Google Scholar
• Murray KK, Boyd RK, Eberlin MN, et al. Definitions of terms relating to mass spectrometry (IUPAC Recommendations 2013. ). Pure Appl Chem. 2013;85(7):1515–1609.
   Web of Science ®Google Scholar
• Marshall G, Blakney T, Chen T, et al. Mass resolution and mass accuracy: how much is enough? Mass Spectrometry. 2013;2(Special_Issue):S0009–S0009. Iss.
   Google Scholar
• Ramanathan R, Korfmacher W. Hrms or hrams? Bioanalysis. 2016;8(16):1639–1640.
   PubMed Web of Science ®Google Scholar
• Huestis MA, Brandt SD, Rana S, et al. Impact of novel psychoactive substances on clinical and forensic toxicology and global public health. Clin Chem. 2017;63(10):1564–1569.
   PubMed Web of Science ®Google Scholar
• Annesley TM. Ion suppression in mass spectrometry. Clin Chem. 2003;49(7):1041–1044.
   PubMed Web of Science ®Google Scholar
• Furey A, Moriarty M, Bane V, et al. Ion suppression; a critical review on causes, evaluation, prevention and applications. Talanta. 2013;115:104–122.
   PubMed Web of Science ®Google Scholar
• Le Blaye O. Variations in internal standard response: some thoughts and real-life cases. Bioanalysis. 2019;11(18):1715–1725.
   PubMed Web of Science ®Google Scholar
• van de Merbe NC, Koster RA, Ohnmacht C. Very complex internal standard response variation in LC-MS/MS bioanalysis: root cause analysis and impact assessment. Bioanalysis. 2019;11(18):1693–1700.
   PubMed Web of Science ®Google Scholar
• Mandatory Guidelines for Federal Workplace Drug Testing Programs. Department of Health and Human Services, Agency: Substance Abuse and Mental Health Services Administration(SAMHSA), HHS. 2017. Available from: https://www.samhsa.gov/sites/default/files/workplace/frn_vol_82_7920_.pdf
   Google Scholar
• Selavka CM. Poppy seed ingestion as a contributing factor to opiate-positive urinalysis results: the Pacific perspective. J Forensic Sci. 1991;36(3):685–696.
   PubMed Web of Science ®Google Scholar
• Mikkelsen SL, Ash KO. Adulterants causing false negatives in illicit drug testing. Clin Chem. 1988;34(11):2333–2336.
   PubMed Web of Science ®Google Scholar
• Dasgupta A. How people try to beat drug testing: issues with urinary adulterants and their detection. Clinical Laboratory News. 2015. Available from: https://www.aacc.org/publications/cln/articles/2015/february/Drug-Testing.aspx
   Google Scholar
• Matriciani B, Huppertz B, Keller R, et al. False-negative results in the immunoassay analysis of drugs of abuse: can adulterants be detected by sample check test? Ann Clin Biochem. 2018;55(3):348–354.
   PubMed Web of Science ®Google Scholar
• Beckett AH, Rowland M, Turner P. Influence of urinary ph on excretion of amphetamine. Lancet. 1965;1(7380):303.
   PubMed Web of Science ®Google Scholar
• Wu AH, Forte E, Casella G, et al. CEDIA for screening drugs of abuse in urine and the effect of adulterants. J Forensic Sci. 1995;40(4):614–618.
   PubMed Web of Science ®Google Scholar
• Urry FM, Komaromy-Hiller G, Staley B, et al. Nitrite adulteration of workplace urine drug-testing specimens. I. Sources and associated concentrations of nitrite in urine and distinction between natural sources and adulteration. J Anal Toxicol. 1998;22(2):89–95.
   PubMed Web of Science ®Google Scholar
• Kapur BM. CBAC: computerized blood alcohol concentration a computer model as a clinical and an educational tool. Ann Biochim Clin Que. 1991;30(2):36–39.
   Google Scholar
• Watson PE, Watson ID, Batt RD. Total body water volumes for adult males and females estimated from simple anthropometric measurements. Am J Clin Nutr. 1980;33(1):27–39.
   PubMed Web of Science ®Google Scholar
• Cederbaum AI. Alcohol metabolism. Clin Liver Dis. 2012;16(4):667–685.
   PubMed Web of Science ®Google Scholar
• Cederbaum AI. Regulation of pathways of alcohol metabolism by the liver. Mt Sinai J Med. 1980;47(3):317–328.
   PubMedGoogle Scholar
• Foti RS, Fisher MB. Assessment of UDP-glucuronosyltransferase catalyzed formation of ethyl glucuronide in human liver microsomes and recombinant UGTs. Forensic Sci Int. 2005;153(2-3):109–116.
   PubMed Web of Science ®Google Scholar
• Dahl H, Stephanson N, Beck O, et al. Comparison of urinary excretion characteristics of ethanol and ethyl glucuronide. J Anal Toxicol. 2002;26(4):201–204.
   PubMed Web of Science ®Google Scholar
• Bostrom H, Vestermark AE. Studies on ester sulphates. 7. On the excretion of sulphate conjugates of primary aliphatic alcohols in the urine of rats. Acta Physiol Scand. 1960;48:88–94.
   PubMedGoogle Scholar
• Manautou JE, Carlson GP. Comparison of pulmonary and hepatic glucuronidation and sulphation of ethanol in rat and rabbit in vitro. Xenobiotica. 1992;22(11):1309–1319.
   PubMed Web of Science ®Google Scholar
• Winek CL, Carfagna M. Comparison of plasma, serum, and whole blood ethanol concentrations. J Anal Toxicol. 1987;11(6):267–268.
   PubMed Web of Science ®Google Scholar
• Jones AW. Top ten defence challenges among drinking drivers in Sweden. Med Sci Law. 1991;31(3):229–238.
   PubMed Web of Science ®Google Scholar
• Iffland R, Jones AW. Evaluating alleged drinking after driving–the hip-flask defence. Part 1. Double blood samples and urine-to-blood alcohol relationship. Med Sci Law. 2002;42(3):207–224.
   PubMed Web of Science ®Google Scholar
• Kronstrand C, Nilsson G, Cherma MD, et al. Evaluating the hip-flask defence in subjects with alcohol on board: An experimental study. Forensic Sci Int. 2019;294:189–195.
   PubMed Web of Science ®Google Scholar
• Alexander WD, Wills PD, Eldred N. Urinary ethanol and diabetes mellitus. Diabet. Diabet Med. 1988;5(5):463–464.
   PubMed Web of Science ®Google Scholar
• Saady JJ, Poklis A, Dalton HP. Production of urinary ethanol after sample collection. J Forensic Sci. 1993;38(6):1467–1471.
   PubMed Web of Science ®Google Scholar
• Goldberg DM, Kapur BM. Enzymes and circulating proteins as markers of alcohol abuse. Clin Chim Acta. 1994;226(2):191–209.
   PubMed Web of Science ®Google Scholar
• Nanau RM, Neuman MG. Biomolecules and biomarkers used in diagnosis of alcohol drinking and in monitoring therapeutic interventions. Biomolecules. 2015;5(3):1339–1385.
   PubMed Web of Science ®Google Scholar
• Borucki K, Schreiner R, Dierkes J, et al. Detection of recent ethanol intake with new markers: comparison of fatty acid ethyl esters in serum and of ethyl glucuronide and the ratio of 5-hydroxytryptophol to 5-hydroxyindole acetic acid in urine. Alcohol Clin Exp Res. 2005;29(5):781–787.
   PubMed Web of Science ®Google Scholar
• Oppolzer D, Barroso M, Gallardo E. Bioanalytical procedures and developments in the determination of alcohol biomarkers in biological specimens. Bioanalysis. 2016;8(3):229–251.
   PubMed Web of Science ®Google Scholar
• Halter CC, Dresen S, Auwaerter V, et al. Kinetics in serum and urinary excretion of ethyl sulfate and ethyl glucuronide after medium dose ethanol intake. Int J Legal Med. 2008;122(2):123–128.
   PubMed Web of Science ®Google Scholar
• Leickly E, McDonell MG, Vilardaga R, et al. High levels of agreement between clinic-based ethyl glucuronide (EtG) immunoassays and laboratory-based mass spectrometry. Am J Drug Alcohol Abuse. 2015;41(3):246–250.
   PubMed Web of Science ®Google Scholar
• Fosen JT, Morini L, Sempio C, et al. Levels of Hair ethyl glucuronide in patients with decreased kidney function: possibility of misclassification of social drinkers. Alcohol Clin Exp Res. 2016;40(3):451–456.
   PubMed Web of Science ®Google Scholar
• Costantino A, DiGregorio EJ, Korn W, et al. The effect of the use of mouthwash on ethylglucuronide concentrations in urine. J Anal Toxicol. 2006;30(9):659–662.
   PubMed Web of Science ®Google Scholar
• Thierauf A, Gnann H, Wohlfarth A, et al. Urine tested positive for ethyl glucuronide and ethyl sulphate after the consumption of "non-alcoholic" beer. Forensic Sci Int. 2010;202(1-3):82–85.
   PubMed Web of Science ®Google Scholar
• Musshoff F, Albermann E, Madea B. Ethyl glucuronide and ethyl sulfate in urine after consumption of various beverages and foods–misleading results? Int J Legal Med. 2010;124(6):623–630.
   PubMed Web of Science ®Google Scholar
• Hoiseth G, Yttredal B, Karinen R, et al. Ethyl glucuronide concentrations in oral fluid, blood, and urine after volunteers drank 0.5 and 1.0 g/kg doses of ethanol. J Anal Toxicol. 2010;34(6):319–324.
   PubMed Web of Science ®Google Scholar
• Helander A, Beck O. Ethyl sulfate: a metabolite of ethanol in humans and a potential biomarker of acute alcohol intake. J Anal Toxicol. 2005;29(5):270–274.
   PubMed Web of Science ®Google Scholar
• Wurst FM, Dresen S, Allen JP, et al. Ethyl sulphate: a direct ethanol metabolite reflecting recent alcohol consumption. Addiction. 2006;101(2):204–211.
   PubMed Web of Science ®Google Scholar
• Hoiseth G, Morini L, Polettini A, et al. Serum/whole blood concentration ratio for ethylglucuronide and ethyl sulfate. J Anal Toxicol. 2009;33(4):208–211.
   PubMed Web of Science ®Google Scholar
• Hoiseth G, Morini L, Polettini A, et al. Blood kinetics of ethyl glucuronide and ethyl sulphate in heavy drinkers during alcohol detoxification. Forensic Sci Int. 2009;188(1-3):52–56.
   PubMed Web of Science ®Google Scholar
• Gnann H, Engelmann C, Skopp G, et al. Identification of 48 homologues of phosphatidylethanol in blood by LC-ESI-MS/MS. Anal Bioanal Chem. 2010;396(7):2415–2423.
   PubMed Web of Science ®Google Scholar
• Gnann H, Thierauf A, Hagenbuch F, et al. Time dependence of elimination of different PEth homologues in alcoholics in comparison with social drinkers. Alcohol Clin Exp Res. 2014;38(2):322–326.
   PubMed Web of Science ®Google Scholar
• Alling C, Gustavsson L, Anggard E. An abnormal phospholipid in rat organs after ethanol treatment. FEBS Lett. 1983;152(1):24–28.
   PubMed Web of Science ®Google Scholar
• Isaksson A, Walther L, Hansson T, et al. Phosphatidylethanol in blood (B-PEth): a marker for alcohol use and abuse. Drug Test Anal. 2011;3(4):195–200.
   PubMed Web of Science ®Google Scholar
• Luginbuhl M, Gaugler S, Weinmann W. Fully automated determination of phosphatidylethanol 16:0/18:1 and 16:0/18:2 in dried blood spots. J Anal Toxicol. 2019;43(6):489–496.
   PubMed Web of Science ®Google Scholar
• Varga A, Hansson P, Johnson G, et al. Normalization rate and cellular localization of phosphatidylethanol in whole blood from chronic alcoholics. Clin Chim Acta. 2000;299(1-2):141–150.
   PubMed Web of Science ®Google Scholar
• Hansson P, Caron M, Johnson G, et al. Blood phosphatidylethanol as a marker of alcohol abuse: levels in alcoholic males during withdrawal. Alcohol Clin Exp Res. 1997;21(1):108–110.
   PubMed Web of Science ®Google Scholar
• Schrock A, Thierauf-Emberger A, Schurch S, et al. Phosphatidylethanol (PEth) detected in blood for 3 to 12 days after single consumption of alcohol-a drinking study with 16 volunteers. Int J Legal Med. 2017;131(1):153–160.
   PubMed Web of Science ®Google Scholar
• Varga A, Hansson P, Lundqvist C, et al. Phosphatidylethanol in blood as a marker of ethanol consumption in healthy volunteers: comparison with other markers. Alcohol Clin Exp Res. 1998;22(8):1832–1837.
   PubMed Web of Science ®Google Scholar
• Laposata EA, Lange LG. Presence of nonoxidative ethanol metabolism in human organs commonly damaged by ethanol abuse. Science. 1986;231(4737):497–499.
   PubMed Web of Science ®Google Scholar
• Lange LG, Bergmann SR, Sobel BE. Identification of fatty acid ethyl esters as products of rabbit myocardial ethanol metabolism. J Biol Chem. 1981;256(24):12968–12973.
   PubMed Web of Science ®Google Scholar
• Laposata EA, Scherrer DE, Mazow C, et al. Metabolism of ethanol by human brain to fatty acid ethyl esters. J Biol Chem. 1987;262(10):4653–4657.
   PubMed Web of Science ®Google Scholar
• Laposata EA, Scherrer DE, Lange LG. Fatty acid ethyl esters in adipose tissue. A laboratory marker for alcohol-related death. Arch Pathol Lab Med. 1989;113(7):762–766.
   PubMed Web of Science ®Google Scholar
• Soderberg BL, Salem RO, Best CA, et al. Fatty acid ethyl esters. Ethanol metabolites that reflect ethanol intake. Am J Clin Pathol. 2003;119(0):94–S99.
   Google Scholar
• Laposata M. Fatty acid ethyl esters: short-term and long-term serum markers of ethanol intake. Clin Chem. 1997;43(8:Pt 2):1527–1534.
   PubMed Web of Science ®Google Scholar
• Kintz P. 2014 consensus for the use of alcohol markers in hair for assessment of both abstinence and chronic excessive alcohol consumption. Forensic Sci Int. 2015;249:A1–A2.
   PubMedGoogle Scholar
• Kintz P, Nicholson D. Testing for ethanol markers in hair: discrepancies after simultaneous quantification of ethyl glucuronide and fatty acid ethyl esters. Forensic Sci Int. 2014;243:44–46.
   PubMed Web of Science ®Google Scholar
• Hagel JM, Krizevski R, Marsolais F, et al. Biosynthesis of amphetamine analogs in plants. Trends Plant Sci. 2012;17(7):404–412.
   PubMed Web of Science ®Google Scholar
• Beckett AH, Rowland M. Rhythmic urinary excretion of amphetamine in man. Nature. 1964;204:1203–1204.
   PubMed Web of Science ®Google Scholar
• Davis JM, Kopin IJ, Lemberger L, et al. Effects of urinary ph on amphetamine metabolism. Ann N Y Acad Sci. 1971;179(6):493–501.
   PubMedGoogle Scholar
• Anggård E, Gunne L-M, Jönsson L-E, et al. Pharmacokinetic and clinical studies on amphetamine-dependent subjects. Eur J Clin Pharmacol. 1970;3(1):3–11.
   Web of Science ®Google Scholar
• Hutson PH, Pennick M, Secker R. Preclinical pharmacokinetics, pharmacology and toxicology of lisdexamfetamine: a novel d-amphetamine pro-drug. Neuropharmacology. 2014;87:41–50.
   PubMed Web of Science ®Google Scholar
• Saitman A, Park HD, Fitzgerald RL. False-positive interferences of common urine drug screen immunoassays: a review. J Anal Toxicol. 2014;38(7):387–396.
   PubMed Web of Science ®Google Scholar
• Drummer OH. Methods for the measurement of benzodiazepines in biological samples. J Chromatogr. 1998;713(1):201–225.
   Web of Science ®Google Scholar
• Maurer H, Pfleger K. Identification and Differentiation of Benzodiazepines and Their Metabolites in Urine by Computerized Gas Chromatography-Mass Spectrometry. J Chromatogr Biomed Appl. 1987;422:85–101.
   Google Scholar
• Baselt RC, editor. Disposition of toxic drugs and chemicals in man. 9th ed. Seal Beach (CA): Biomedical Publications; 2011. p. 376–377.
   Google Scholar
• Nasky KM, Cowan GL, Knittel DR. False-positive urine screening for benzodiazepines: an association with sertraline?: a two-year retrospective chart analysis. Psychiatry (Edgmont)). 2009;6(7):36–39.
   PubMedGoogle Scholar
• Battino D, Avanzini G, Bossi L, et al. Plasma levels of primidone and its metabolite phenobarbital: effect of age and associated therapy. Ther Drug Monit. 1983;5(1):73–79.
   PubMed Web of Science ®Google Scholar
• Pertwee RG. Cannabinoid pharmacology: the first 66 years. Br J Pharmacol. 2009;147(S1):S163–S171.
   Google Scholar
• ElSohly MA, Slade D. Chemical constituents of marijuana: the complex mixture of natural cannabinoids. Life Sci. 2005;78(5):539–548.
   PubMed Web of Science ®Google Scholar
• Radwan MM, ElSohly MA, Slade D, et al. Biologically active cannabinoids from high-potency Cannabis sativa. J Nat Prod. 2009;72(5):906–911.
   PubMed Web of Science ®Google Scholar
• Carlini EA. The good and the bad effects of (-) trans-delta-9-tetrahydrocannabinol (Delta 9-THC) on humans. Toxicon. 2004;44(4):461–467.
   PubMed Web of Science ®Google Scholar
• Thomas BF, Compton DR, Martin BR. Characterization of the lipophilicity of natural and synthetic analogs of delta 9-tetrahydrocannabinol and its relationship to pharmacological potency. J Pharmacol Exp Ther. 1990;255(2):624–630.
   Google Scholar
• Ashton CH. Pharmacology and effects of cannabis: a brief review. Br J Psychiatry. 2001;178:101–106.
   PubMed Web of Science ®Google Scholar
• Grotenhermen F. Pharmacokinetics and pharmacodynamics of cannabinoids. Clin Pharmacokinet. 2003;42(4):327–360.
   PubMed Web of Science ®Google Scholar
• Huestis MA, Henningfield JE, Cone EJ. Blood cannabinoids. I. Absorption of THC and formation of 11-OH-THC and THCCOOH during and after smoking marijuana. J Anal Toxicol. 1992;16(5):276–282.
   PubMed Web of Science ®Google Scholar
• Huestis MA. Human cannabinoid pharmacokinetics. Chem Biodivers. 2007;4(8):1770–1804.
   PubMed Web of Science ®Google Scholar
• Martin JH, Schneider J, Lucas CJ, et al. Exogenous cannabinoid efficacy: merely a pharmacokinetic interaction? Clin Pharmacokinet. 2018;57(5):539–545.
   PubMed Web of Science ®Google Scholar
• Solowij N, Broyd SJ, van Hell HH, et al. A protocol for the delivery of cannabidiol (CBD) and combined CBD and 9-tetrahydrocannabinol (THC) by vaporisation. BMC Pharmacol Toxicol. 2014;15:58.
   PubMed Web of Science ®Google Scholar
• Taylor M, Lees R, Henderson G, et al. Comparison of cannabinoids in hair with self-reported cannabis consumption in heavy, light and non-cannabis users. Drug & Alcohol Review. 2017;36(2):220–226.
   PubMed Web of Science ®Google Scholar
• McShane AJ, S B, Heideloff C, et al. Falsely low urine d9-tetrahydrocannabinol COOH levels from metal lid specimen containers with a low-density polyethylene lining. Jrnl App Lab Med. 2017;1(5):590–592.
   PubMedGoogle Scholar
• Clark TM, Jones JM, Hall AG, et al. Theoretical explanation for reduced body mass index and obesity rates in cannabis users. Cannabis Cannabinoid Res. 2018;3(1):259–271.
   PubMedGoogle Scholar
• Goodwin RS, Darwin WD, Chiang CN, et al. Urinary elimination of 11-nor-9-carboxy-delta9-tetrahydrocannnabinol in cannabis users during continuously monitored abstinence. J Anal Toxicol. 2008;32(8):562–569.
   PubMed Web of Science ®Google Scholar
• Stout SM, Cimino NM. Exogenous cannabinoids as substrates, inhibitors, and inducers of human drug metabolizing enzymes: a systematic review. Drug Metab Rev. 2014;46(1):86–95.
   PubMed Web of Science ®Google Scholar
• Kapur BM, Lala PK, Shaw JL. Pharmacogenetics of chronic pain management. Clin Biochem. 2014;47(13-14):1169–1187.
   PubMed Web of Science ®Google Scholar
• Rollins DE, Jennison TA, Jones G. Investigation of interference by nonsteroidal anti-inflammatory drugs in urine tests for abused drugs. Clin Chem. 1990;36(4):602–606.
   PubMed Web of Science ®Google Scholar
• Niedbala S, Kardos K, Salamone S, et al. Passive cannabis smoke exposure and oral fluid testing. J Anal Toxicol. 2004;28(7):546–552.
   PubMed Web of Science ®Google Scholar
• Morland J, Bugge A, Skuterud B, et al. Cannabinoids in blood and urine after passive inhalation of Cannabis smoke. J Forensic Sci. 1985;30(4):997–1002.
   PubMed Web of Science ®Google Scholar
• Solowij N, Galettis P, Broyd SJ, et al. Second-Hand exposure of staff administering vaporised cannabinoid products to patients in a hospital setting. Drugs in R & D. 2018;18(1):41–44.
   Google Scholar
• Valentine JL, Bryant PJ, Gutshall PL, et al. Detection of d9-tetrahydrocannabinol in human breath following marijuana smoking. Anal Lett. 1979;12(8):867–880.
   Web of Science ®Google Scholar
• Luo YR, Yun C, Lynch KL. Quantitation of cannabinoids in breath samples using a novel derivatization LC–MS/MS assay with ultra-high sensitivity. J Anal Toxicol. 2019;43(5):331–339.
   PubMed Web of Science ®Google Scholar
• Coe MA, Jufer Phipps RA, Cone EJ, et al. Bioavailability and pharmacokinetics of oral cocaine in humans. J Anal Toxicol. 2018;42(5):285–292.
   PubMed Web of Science ®Google Scholar
• Fish F, Wilson WD. Excretion of cocaine and its metabolites in man. J Pharm Pharmacol. 1969;21(Suppl):135–138.
   Google Scholar
• Kogan MJ, Verebey KG, DePace AC, et al. Quantitative determination of benzoylecgonine and cocaine in human biofluids by gas-liquid chromatography. Anal Chem. 1977;49(13):1965–1969.
   PubMed Web of Science ®Google Scholar
• Inaba T, Stewart DJ, Kalow W. Metabolism of cocaine in man. Clin Pharmacol Ther. 1978;23(5):547–552.
   PubMed Web of Science ®Google Scholar
• Stewart DJ, Inaba T, Lucassen M, et al. Cocaine metabolism: cocaine and norcocaine hydrolysis by liver and serum esterases. Clin Pharmacol Ther. 1979;25(4):464–468.
   PubMed Web of Science ®Google Scholar
• Baselt RC. Stability of cocaine in biological fluids. J Chromatogr. 1983;268(3):502–505.
   PubMed Web of Science ®Google Scholar
• Isenschmid DS, Fischman MW, Foltin RW, et al. Concentration of cocaine and metabolites in plasma of humans following intravenous administration and smoking of cocaine. J Anal Toxicol. 1992;16(5):311–314.
   PubMed Web of Science ®Google Scholar
• Barnett G, Hawks R, Resnick R. Cocaine pharmacokinetics in humans. J Ethnopharmacol. 1981;3(2-3):353–366.
   PubMed Web of Science ®Google Scholar
• Jatlow P, Elsworth JD, Bradberry CW, et al. Cocaethylene: a neuropharmacologically active metabolite associated with concurrent cocaine-ethanol ingestion. Life Sci. 1991;48(18):1787–1794.
   PubMed Web of Science ®Google Scholar
• Rose JS. Cocaethylene: a current understanding of the active metabolite of cocaine and ethanol. Am J Emerg Med. 1994;12(4):489–490.
   PubMed Web of Science ®Google Scholar
• Mack A. Examination of the evidence for off-label use of gabapentin. J Manag Care Pharm. 2003;9(6):559–568.
   PubMedGoogle Scholar
• Senderovich H, Jeyapragasan G. Is there a role for combined use of gabapentin and pregabalin in pain control? Too good to be true? Curr Med Res Opin. 2018;34(4):677–682.
   PubMed Web of Science ®Google Scholar
• Burns ML, Kinge E, Stokke OM, et al. Therapeutic drug monitoring of gabapentin in various indications. Acta Neurol Scand. 2019;139(5):446–454.
   PubMed Web of Science ®Google Scholar
• Bonnet U, Scherbaum N. How addictive are gabapentin and pregabalin? A systematic review. Eur Neuropsychopharmacol. 2017;27(12):1185–1215.
   PubMed Web of Science ®Google Scholar
• Trescot AM, Datta S, Lee M, et al. Opioid pharmacology. Pain Physician. 2008;11(2 Suppl):S133–S153.
   PubMed Web of Science ®Google Scholar
• Zerell U, Ahrens B, Gerz P. Documentation of a heroin manufacturing process in Afghanistan. Bull Narc. 2005;57(1-2):11–31.
   PubMedGoogle Scholar
• von EM, Villen T, Svensson JO, et al. Interpretation of the presence of 6-monoacetylmorphine in the absence of morphine-3-glucuronide in urine samples: evidence of heroin abuse. Ther Drug Monit. 2003;25(5):645–648.
   PubMed Web of Science ®Google Scholar
• Ohno S, Kawana K, Nakajin S. Contribution of UDP-glucuronosyltransferase 1A1 and 1A8 to morphine-6-glucuronidation and its kinetic properties. Drug Metab Dispos. 2008;36(4):688–694.
   PubMed Web of Science ®Google Scholar
• Coffman BL, Rios GR, King CD, et al. Human UGT2B7 catalyzes morphine glucuronidation. Drug Metab Dispos. 1997;25(1):1–4.
   PubMed Web of Science ®Google Scholar
• Caraco Y, Tateishi T, Guengerich FP, et al. Microsomal codeine N-demethylation: cosegregation with cytochrome P4503A4 activity. Drug Metab Dispos. 1996;24(7):761–764.
   PubMed Web of Science ®Google Scholar
• Yue QY, Hasselstrom J, Svensson JO, et al. Pharmacokinetics of codeine and its metabolites in Caucasian healthy volunteers: comparisons between extensive and poor hydroxylators of debrisoquine. Br J Clin Pharmacol. 1991;31(6):635–642.
   PubMed Web of Science ®Google Scholar
• Oyler JM, Cone EJ, Joseph RE, Jr, et al. Identification of hydrocodone in human urine following controlled codeine administration. J Anal Toxicol. 2000;24(7):530–535.
   PubMed Web of Science ®Google Scholar
• Gasche Y, Daali Y, Fathi M, et al. Codeine intoxication associated with ultrarapid CYP2D6 metabolism. N Engl J Med. 2004;351(27):2827–2831.
   PubMed Web of Science ®Google Scholar
• Koren G, Cairns J, Chitayat D, et al. Pharmacogenetics of morphine poisoning in a breastfed neonate of a codeine-prescribed mother. Lancet. 2006;368(9536):704.
   PubMed Web of Science ®Google Scholar
• DePriest AZ, Puet BL, Holt AC, et al. Metabolism and disposition of prescription opioids: a review. Forensic Sci Rev. 2015;27(2):115–145.
   PubMedGoogle Scholar
• Valtier S, Bebarta VS. Excretion profile of hydrocodone, hydromorphone and norhydrocodone in urine following single dose administration of hydrocodone to healthy volunteers. J Anal Toxicol. 2012;36(7):507–514.
   PubMed Web of Science ®Google Scholar
• Cone EJ, Caplan YH, Moser F, et al. Evidence that morphine is metabolized to hydromorphone but not to oxymorphone. J Anal Toxicol. 2008;32(4):319–323.
   PubMed Web of Science ®Google Scholar
• Mandatory Guidelines for Federal Workplace Drug Testing Programs. Department of Health and Human Services. 2010. Available from: https://www.gpo.gov/fdsys/pkg/FR-2010-04-30/pdf/2010-10118.pdf
   Google Scholar
• Smith ML, Nichols DC, Underwood P, et al. Morphine and codeine concentrations in human urine following controlled poppy seeds administration of known opiate content. Forensic Sci Int. 2014;241:87–90.
   PubMed Web of Science ®Google Scholar
• ElSohly HN, Stanford DF, Jones AB, et al. Gas chromatographic/mass spectrometric analysis of morphine and codeine in human urine of poppy seed eaters. J Forensic Sci. 1988;33(2):347–356.
   PubMed Web of Science ®Google Scholar
• Hayes LW, Krasselt WG, Mueggler PA. Concentrations of morphine and codeine in serum and urine after ingestion of poppy seeds. Clin Chem. 1987;33(6):806–808.
   PubMed Web of Science ®Google Scholar
• Samano KL, Clouette RE, Rowland BJ, et al. Concentrations of morphine and codeine in Paired oral fluid and urine specimens following ingestion of a poppy seed roll and raw poppy seeds. J Anal Toxicol. 2015;39(8):655–661.
   PubMed Web of Science ®Google Scholar
• Latta KS, Ginsberg B, Barkin RL. Meperidine: a critical review. Am J Ther. 2002;9(1):53–68.
   PubMedGoogle Scholar
• Kranke P, Weibel S. Pain relief during labour: challenging the use of intramuscular pethidine. Lancet. 2018;392(10148):617–619.
   PubMed Web of Science ®Google Scholar
• Zhang J, Burnell JC, Dumaual N, et al. Binding and hydrolysis of meperidine by human liver carboxylesterase hCE-1. J Pharmacol Exp Ther. 1999;290(1):314–318.
   PubMed Web of Science ®Google Scholar
• Verbeeck RK, Branch RA, Wilkinson GR. Meperidine disposition in man: influence of urinary pH and route of administration. Clin Pharmacol Ther. 1981;30(5):619–628.
   PubMed Web of Science ®Google Scholar
• Lehotay DC, George S, Etter ML, et al. Free and bound enantiomers of methadone and its metabolite, EDDP in methadone maintenance treatment: relationship to dosage. ? Clin Biochem. 2005;38(12):1088–1094.
   PubMed Web of Science ®Google Scholar
• Fainsinger R, Schoeller T, Bruera E. Methadone in the management of cancer pain: a review. Pain. 1993;52(2):137–147.
   PubMed Web of Science ®Google Scholar
• Ripamonti C, Zecca E, Bruera E. An update on the clinical use of methadone for cancer pain. Pain. 1997;70(2-3):109–115.
   PubMed Web of Science ®Google Scholar
• Garrido MJ, Aguirre C, Niz IF, et al. Alpha1-acid glycoprotein (AAG) and serum protein binding of methadone in heroin addicts with abstinence syndrome. CP. 2000;38(01):35–40.
   Google Scholar
• Pond SM, Kreek MJ, Tong TG, et al. Altered methadone pharmacokinetics in methadone-maintained pregnant women. J Pharmacol Exp Ther. 1985;233(1):1–6.
   PubMed Web of Science ®Google Scholar
• Sullivan HR, Smits SE, Due SL, et al. Metabolism of d-methadone: Isolation and identification of analgesically active metabolites. Life Sci. 1972;11:1093–1104.
   Google Scholar
• Nilsson MI, Meresaar U, Anggard E. Clinical pharmacokinetics of methadone. Acta Anaesthesiol Scand. 1982; 26Supplementum.(74):66–69.
   Web of Science ®Google Scholar
• Wolff K, Strang J. Therapeutic drug monitoring for methadone: scanning the horizon. Eur Addict Res. 1999;5(1):36–42.
   PubMed Web of Science ®Google Scholar
• Eap CB. On the usefulness of therapeutic drug monitoring of methadone. Eur Addict Res. 2000;6(1):31–33.
   PubMed Web of Science ®Google Scholar
• Bell J, Seres V, Bowron P, et al. The use of serum methadone levels in patients receiving methadone maintenance. Clin Pharmacol Ther. 1988;43(6):623–629.
   PubMed Web of Science ®Google Scholar
• de Vos JW, Geerlings PJ, van den BW, et al. Pharmacokinetics of methadone and its primary metabolite in 20 opiate addicts. Eur J Clin Pharmacol. 1995;48(5):361–366.
   PubMed Web of Science ®Google Scholar
• Kapur BM, Hutson JR, Chibber T, et al. Methadone: a review of drug-drug and pathophysiological interactions. Crit Rev Clin Lab Sci. 2011;48(4):171–195.
   PubMed Web of Science ®Google Scholar
• Li Y, Kantelip JP, Gerritsen-van SP, et al. Interindividual variability of methadone response: impact of genetic polymorphism. Mol Diagn Ther. 2008;12(2):109–124.
   PubMed Web of Science ®Google Scholar
• Wolff K, Rostami-Hodjegan A, Shires S, et al. The pharmacokinetics of methadone in healthy subjects and opiate users. Br J Clin Pharmacol. 2003;44(4):325–334.
   Google Scholar
• Eap CB, Buclin T, Baumann P. Interindividual variability of the. Clin Pharmacokinet. 2002;41(14):1153–1193.
   PubMed Web of Science ®Google Scholar
• Cornell University JaSIWMC. Calculate the half-life of a drug from two plasma levels separated by a time interval. 2000. [cited 2019 Mar 28]. Available from: http://www-users.med.cornell.edu/∼spon/picu/calc/halfcalc.htm
   Google Scholar
• Medellin-Garibay SE, Correa-Lopez T, Romero-Mendez C, et al. Limited sampling strategies to predict the area under the concentration-time curve for rifampicin. Ther Drug Monit. 2014;36(6):746–751.
   PubMed Web of Science ®Google Scholar
• Cone EJ, Gorodetzky CW, Yousefnejad D, et al. The metabolism and excretion of buprenorphine in humans. Drug Metab Dispos. 1984;12(5):577–581.
   PubMed Web of Science ®Google Scholar
• Chang Y, Moody DE. Glucuronidation of buprenorphine and norbuprenorphine by human liver microsomes and UDP-glucuronosyltransferases. Drug Metab Lett. 2009;3(2):101–107.
   PubMedGoogle Scholar
• Brown SM, Campbell SD, Crafford A, et al. Glycoprotein is a major determinant of norbuprenorphine brain exposure and antinociception. J Pharmacol Exp Ther. 2012;343(1):53–61. P
   PubMed Web of Science ®Google Scholar
• Kronstrand R, Nystrom I, Andersson M, et al. Urinary detection times and metabolite/parent compound ratios after a single dose of buprenorphine. J Anal Toxicol. 2008;32(8):586–593.
   PubMed Web of Science ®Google Scholar
• Donroe JH, Holt SR, O’Connor PG, et al. Interpreting quantitative urine buprenorphine and norbuprenorphine levels in office-based clinical practice. Drug Alcohol Depend. 2017;180:46–51.
   PubMed Web of Science ®Google Scholar
• Melanson SE, Snyder ML, Jarolim P, et al. A new highly specific buprenorphine immunoassay for monitoring buprenorphine compliance and abuse. J Anal Toxicol. 2012;36(3):201–206.
   PubMed Web of Science ®Google Scholar
• Birch MA, Couchman L, Pietromartire S, et al. False-positive buprenorphine by CEDIA in patients prescribed amisulpride or sulpiride. J Anal Toxicol. 2013;37(4):233–236.
   PubMed Web of Science ®Google Scholar
• Sorensen LK, Hasselstrom JB. Ascorbic acid improves the stability of buprenorphine in frozen whole blood samples. J Anal Toxicol. 2019;43(6):482–488.
   PubMed Web of Science ®Google Scholar
• Vallejo R, Barkin RL, Wang VC. Pharmacology of opioids in the treatment of chronic pain syndromes. Pain Physician. 2011;14(4):E343–E360.
   PubMed Web of Science ®Google Scholar
• Wang BT, Colby JM, Wu AH, et al. Cross-reactivity of acetylfentanyl and risperidone with a fentanyl immunoassay. J Anal Toxicol. 2014;38(9):672–675.
   PubMed Web of Science ®Google Scholar
• Hendrickson RG, Akpunonu P, Hughes AR, et al. Highly potent fentanyl analogs: apnea from exposure to small quantities of s-hydroxyfentanyl and furanylfentanyl. Clin Toxicol (Phila)). 2019;57(9):813–815.
   PubMed Web of Science ®Google Scholar
• Lozier MJ, Boyd M, Stanley C, et al. Acetyl fentanyl, a novel fentanyl analog, causes 14 overdose deaths in rhode island, march-may 2013. J Med Toxicol. 2015;11(2):208–217.
   PubMed Web of Science ®Google Scholar
• Finkelstein MJ, Chronister CW, Stanley C, et al. Analysis of acetyl fentanyl in postmortem specimens by gas chromatography-mass spectrometry (GC-MS): method validation and case report. J Anal Toxicol. 2019;43(5):392–398.
   PubMed Web of Science ®Google Scholar
• Lalovic B, Phillips B, Risler LL, et al. Quantitative contribution of CYP2D6 and CYP3A to oxycodone metabolism in human liver and intestinal microsomes. Drug Metab Dispos. 2004;32(4):447–454.
   PubMed Web of Science ®Google Scholar
• Samer CF, Daali Y, Wagner M, et al. Genetic polymorphisms and drug interactions modulating CYP2D6 and CYP3A activities have a major effect on oxycodone analgesic efficacy and safety. Br J Pharmacol. 2010;160(4):919–930.
   PubMed Web of Science ®Google Scholar
• Liukas A, Kuusniemi K, Aantaa R, et al. Plasma concentrations of oral oxycodone are greatly increased in the elderly. Clin Pharmacol Ther. 2008;84(4):462–467.
   PubMed Web of Science ®Google Scholar
• Poyhia R, Seppala T, Olkkola KT, et al. The pharmacokinetics and metabolism of oxycodone after intramuscular and oral administration to healthy subjects. Br J Clin Pharmacol. 1992;33(6):617–621.
   PubMed Web of Science ®Google Scholar
• Sloan P. Review of oral oxymorphone in the management of pain. Ther Clin Risk Manag. 2008;4(4):777–787.
   PubMedGoogle Scholar
• Adams MP, Ahdieh H. Pharmacokinetics and dose-proportionality of oxymorphone extended release and its metabolites: results of a randomized crossover study. Pharmacotherapy: J Hum Pharmacol Drug Ther. 2004;24(4):468–476.
   Google Scholar
• Vandenbossche J, Van PA, Richards H. Single-dose pharmacokinetic study of tramadol extended-release tablets in children and adolescents. Clini Pharmacol Drug Develop. 2016;5(5):343–353.
   PubMed Web of Science ®Google Scholar
• Grond S, Sablotzki A. Clinical pharmacology of tramadol. Clin Pharmacokinet. 2004;43(13):879–923.
   PubMed Web of Science ®Google Scholar
• Khosrojerdi H, Alipour TG, Danaei GH, et al. Tramadol half life is dose dependent in overdose. Daru. 2015;23:22.
   PubMed Web of Science ®Google Scholar
• Danso D, Langman LJ, Jannetto PJ. Targeted Opioid Screening Assay for Pain Management Using High-Resolution Mass Spectrometry. Methods Mol Biol. 2019;1872:41–50.
   PubMedGoogle Scholar
• Sansone RA, Sansone LA. Tramadol: seizures, serotonin syndrome, and coadministered antidepressants. Psychiatry (Edgmont)). 2009;6(4):17–21.
   PubMedGoogle Scholar
• Verbeurgt P, Mamiya T, Oesterheld J. How common are drug and gene interactions? Prevalence in a sample of 1143 patients with CYP2C9, CYP2C19 and CYP2D6 genotyping. Pharmacogenomics. 2014;15(5):655–665.
   PubMed Web of Science ®Google Scholar
• Perez de los CJ, Sinol N, Trujols J, et al. Association of CYP2D6 ultrarapid metabolizer genotype with deficient patient satisfaction regarding methadone maintenance treatment. Drug Alcohol Depend. 2007;89(2-3):190–194.
   PubMed Web of Science ®Google Scholar
• Fonseca F, de la TR, Diaz L, et al. Contribution of cytochrome P450 and ABCB1 genetic variability on methadone pharmacokinetics, dose requirements, and response. PLoS One. 2011;6(5):e19527.
   PubMed Web of Science ®Google Scholar
• Bell GC, Crews KR, Wilkinson MR, et al. Development and use of active clinical decision support for preemptive pharmacogenomics. J Am Med Inform Assoc. 2014;21(e1):e93–e99.
   PubMed Web of Science ®Google Scholar
• Agarwal D, Udoji MA, Trescot A, et al. Genetic testing for opioid pain management: a primer. Pain Ther. 2017;6(1):93–105.
   PubMed Web of Science ®Google Scholar
• Sallee FR, DeVane CL, Ferrell RE. Fluoxetine-related death in a child with cytochrome P-450 2D6 genetic deficiency. J Child Adolesc Psychopharmacol. 2000;10(1):27–34.
   PubMed Web of Science ®Google Scholar
• Flockhart DA. Drug Interactions. Cytochrome P450 Drug Interaction Table. Indiana University School of Medicine 2007. [cited 2020 Apr 06]. Available from: https://drug-interactions.medicine.iu.edu/MainTable.aspx
   Google Scholar
• Shiran MR, Chowdry J, Rostami-Hodjegan A, et al. A discordance between cytochrome P450 2D6 genotype and phenotype in patients undergoing methadone maintenance treatment. Br J Clin Pharmacol. 2003;56(2):220–224.
   PubMed Web of Science ®Google Scholar